Table 2 Baseline characteristics of SARS-CoV-2-positive participants and the association between MGUS and severity of COVID-19.
From: Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study
No MGUS | MGUS | HC-MGUS | LC-MGUS | |
|---|---|---|---|---|
n | 1004 | 56 | 35 | 21 |
Mean age (SD) | 59 (10) | 65 (11) | 65 (12) | 65 (10) |
Men | 448 (45%) | 30 (54%) | 22 (63%) | 8 (38%) |
Person-days | 16,589 | 962 | – | – |
Emergency outpatient visit | 176 (18%) | 12 (20%) | 7 (20%) | 5 (24%) |
Hospital admission | 105 (11%) | 11 (20%) | 8 (23%) | 3 (14%) |
Intensive care unit admission | 20 (2%) | 3 (5%) | 2 (6%) | 1 (5%) |
Death | 5 (1%) | 0 (0%) | 0 (0%) | 0 (0%) |
Emergency outpatient visit or worse | 214 (21%) | 16 (29%) | 10 (29%) | 6 (29%) |
OR (95% CI)a | Ref | 0.99 (0.52–1.91) | 0.90 (0.39–2.08) | 1.10 (0.39–3.10) |
Hospital admission or worse | 106 (11%) | 11 (20%) | 8 (23%) | 3 (14%) |
OR (95% CI)a | Ref | 1.13 (0.52–2.46) | 1.25 (0.49–3.19) | 0.83 (0.21–3.29) |
